Advanced Neurology Specialists

Great Falls, Montana 95405

0 studies enrolling now · 18 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Central Neuropathic Pain, Diabetes, Essential Tremor, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Myocardial Infarction, Parkinson's Disease, Pseudobulbar Affect (PBA), Relapsing Multiple Sclerosis, Stroke

Studies at this site

• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) — Stopped early
• Prospective Study for Symptomatic Relief of ET With Cala Therapy — Completed
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis — Completed
• Insulin Resistance Intervention After Stroke Trial — Completed
• Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" — Completed
• Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS — Completed
• Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients — Completed
• Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) — Completed
• Study of Fampridine-SR Tablets in Multiple Sclerosis Patients — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial — Completed